Read Time: 3 minutes
The National Cancer Institute awarded investigators at Huntsman Cancer Institute a grant totaling more than $3 million to conduct a clinical trial to see if combining creatine monohydrate supplementation and resistance exercise training helps preserve muscle in people who have metastatic prostate cancer. Loss of muscle mass is a major side effect of treatment for prostate cancer. Creatine monohydrate supplementation, a naturally occurring molecule in the body, helps combat fatigue and provides more energy, resulting in better workouts. Researchers hypothesize that taking creatine monohydrate supplementation while participating in resistance training will preserve muscle mass.
To test this, 200 men with metastatic prostate cancer will take part in a 52-week, double-blind, placebo-controlled, randomized trial during treatment. One group of patients will receive the creatine monohydrate supplementation and the other will receive a placebo. Both groups will engage in an individualized, supervised, telehealth-delivered resistance training program with the Personal Optimism With Exercise Recovery (POWER) fitness program at Huntsman Cancer Institute. Study participants and researchers will not know who is getting the supplement or placebo.
鈥淚t鈥檚 important for patients to keep the muscle mass they already have to help maintain independence, quality of life, and reduce other cancer treatment-related side effects.鈥
鈥淥nce patients start receiving treatment for their metastatic prostate cancer, they can no longer gain muscle mass because the treatment blocks the androgen signaling, which helps to make testosterone,鈥 says , member of the at Huntsman Cancer Institute, assistant professor in the at the University of Utah, and one of the lead investigators of the clinical trial. 鈥淚f your body doesn鈥檛 make testosterone, you can鈥檛 build muscle mass, but you can lose it. It鈥檚 important for patients to keep the muscle mass they already have to help maintain independence, quality of life, and reduce other cancer treatment-related side effects. Also, more muscle mass is also linked to higher survival rates.鈥
Coletta wishes to thank the patients who participated in the 12-week trial that provided preliminary data for this large grant, along with members of the Salt Lake City Prostate Cancer Community Support Group, who assisted in the planning process of the proposed trial. She would also like to thank the POWER program, Huntsman Cancer Institute鈥檚 clinical trials office, and her investigative team members: Neeraj Agarwal, MD, physician-scientist at Huntsman Cancer Institute and co-lead on this trial, Benjamin Maughan, MD, PHARMD, and Manish Kohli, MD, physician-scientists at Huntsman Cancer Institute, , chief scientific officer and executive director of the comprehensive cancer center at Huntsman Cancer Institute, and , member of the at Huntsman Cancer Institute.
鈥淭his is an exceptional collaboration between exercise scientists and top clinical trialists at Huntsman Cancer Institute鈥 says Ulrich. 鈥淭ogether this team will find important answers for men with prostate cancer.鈥
鈥淚t鈥檚 so exciting that we now have the support and resources to take this research to the next level,鈥 Coletta says. 鈥淭his is just the start of what鈥檚 to come from our group to improve quality of life for cancer patients.鈥
The study was supported by the National Institutes of Health/National Cancer Institute including P30 CA042014 and Huntsman Cancer Foundation.
Media Contact
Heather Simonsen
Public Affairs Senior Manager
Huntsman Cancer Institute
801 581-3194
public.affairs@hci.utah.edu
About Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, Idaho, Montana, Nevada, and Wyoming. With a legacy of innovative cancer research, groundbreaking discoveries, and world-class patient care, we are transforming the way cancer is understood, prevented, diagnosed, treated, and survived. Huntsman Cancer Institute focuses on delivering the most advanced cancer healing and prevention through scientific breakthroughs and cutting-edge technology to advance cancer treatments of the future beyond the standard of care today. We have more than 300 open clinical trials and 250 research teams studying cancer. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient鈥檚 unique disease. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.